Notification of Preliminary Results
Analyst Conference Call and Webcast
Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the 12 months ended 31 December 2020 on Tuesday 23 March 2021.
A conference call for analysts will be held at 10.30am on 23 March 2021; analysts who require dial-in details, please contact Buchanan at alliancepharma@buchanan.uk.com.
A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 23 March 2021 at this link:
https://webcasting.buchanan.uk.com/broadcast/60180f8da6bfbf43d06ac2ea
The recorded webcast will also be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors/.
For more information, please contact Buchanan on 020 7466 5000 or email alliancepharma@buchanan.uk.com.
For further information:
Alliance Pharma plc
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
+ 44 (0)1249 466966
Buchanan
Mark Court / Sophie Wills / Hannah Ratcliff
alliancepharma@buchanan.uk.com
+ 44 (0)20 7466 5000
Numis Securities Limited
Nominated Adviser: Freddie Barnfield / Huw Jeremy
Corporate Broking: James Black
+ 44 (0)20 7260 1000
Investec Bank plc
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
+ 44 (0)20 7597 5970
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com